MOTS-c: The Mitochondrial Peptide That Regulates Energy and Metabolism

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a peptide of 16 amino acids encoded within the mitochondrial genome — specifically within the 12S ribosomal RNA gene. It was discovered in 2015 by Changhan David Lee and Pinchas Cohen at the University of Southern California Leonard Davis School of Gerontology and published in the journal Cell Metabolism.

What makes MOTS-c extraordinary is its origin: the mitochondrial genome is an ancient, evolutionarily conserved genome separate from nuclear DNA that contains only 37 genes (compared to ~20,000 in the nuclear genome). Peptides encoded by mitochondrial DNA that function as systemic hormones were essentially unknown before MOTS-c's discovery. MOTS-c is part of a broader class called "mitokines" — mitochondria-derived peptides that signal to other cells and tissues.

How MOTS-c Works

AMPK Activation

MOTS-c's primary downstream signaling target is AMPK (AMP-activated protein kinase) — often described as the cell's "master energy sensor." AMPK activation triggers a cascade of beneficial metabolic effects:

• Increased glucose uptake by cells (independent of insulin)
• Enhanced fatty acid oxidation (fat burning)
• Mitochondrial biogenesis (creation of new mitochondria)
• Suppression of inflammation
• Activation of autophagy (cellular waste removal)

Interestingly, this is the same pathway activated by exercise and by the diabetes drug metformin — suggesting MOTS-c may mediate some of the metabolic benefits of physical activity.

Insulin Sensitivity

MOTS-c dramatically improves insulin sensitivity in animal models. In obese, insulin-resistant mice, MOTS-c administration prevented diet-induced obesity and type 2 diabetes, even without changes in diet. It enhanced glucose tolerance, reduced fasting insulin, and improved liver fat metabolism. This positions MOTS-c as a highly interesting compound for metabolic disease and insulin resistance.

Anti-Inflammatory Effects

Chronic low-grade inflammation (inflammaging) is a key driver of aging and age-related disease. MOTS-c reduces production of pro-inflammatory cytokines and modulates macrophage function, potentially contributing to its anti-aging effects at the cellular level.

Physical Performance and Muscle Function

MOTS-c enhances physical performance in animal models — treated mice show greater running endurance, improved grip strength, and higher skeletal muscle oxidative capacity. The mechanism involves enhanced mitochondrial efficiency and substrate utilization in muscle. This has obvious implications for exercise performance and age-related muscle loss (sarcopenia).

MOTS-c and Aging

The connection between MOTS-c and aging is one of the most exciting aspects of this peptide:

• MOTS-c levels decline with age in both animals and humans
• In centenarians (people living past 100), specific MOTS-c genetic variants are enriched, suggesting a potential role in exceptional longevity
• MOTS-c administration in aged mice improves physical capacity and metabolic health, partially reversing age-related decline
• MOTS-c levels increase with exercise — and decrease with sedentary aging — mirroring the metabolic divergence between active and sedentary individuals

The 2021 paper "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis" (Nature Communications) was a landmark publication demonstrating that MOTS-c is essentially a molecular mediator of exercise benefits — and that supplementing it in aged mice produced exercise-like metabolic improvements.

MOTS-c and Exercise: The "Exercise Peptide"

Perhaps the most intriguing aspect of MOTS-c is its role as a mediator of exercise benefits. During physical activity, skeletal muscle mitochondria produce and release MOTS-c into circulation, where it travels to fat tissue, liver, and brain to coordinate systemic metabolic adaptation. This is why exercise improves insulin sensitivity, reduces inflammation, and supports brain health — MOTS-c (along with other mitokines like humanin) is part of the molecular explanation for these wide-ranging benefits.

For individuals who cannot exercise adequately (due to injury, disability, or illness), MOTS-c supplementation offers a conceptually compelling way to partially replicate some metabolic benefits of physical activity.

Human Research and Clinical Status

MOTS-c is currently in the preclinical-to-early-clinical research phase. As of 2026, published human trials are limited. Animal and in-vitro data are compelling, and several research groups are pursuing clinical trials, particularly for:

• Type 2 diabetes and insulin resistance
• Age-related metabolic decline
• Sarcopenia (muscle loss with aging)
• Physical performance in aging populations

Early-adopter clinical use is occurring in longevity medicine and peptide therapy practices, drawing on the extensive animal data and favorable safety profile.

Administration and Dosing

MOTS-c is available through compounding pharmacies as a lyophilized powder for reconstitution. It is typically administered as a subcutaneous injection. Because endogenous MOTS-c levels rise with exercise, injection is often timed around exercise sessions in clinical protocols.

Common protocols:

• 5–10 mg subcutaneous injection, 3–5 times per week
• Often cycled (e.g., 4–8 weeks on, 4 weeks off)
• Frequently combined with other mitochondria-supporting compounds (NAD+ precursors, CoQ10, MitoQ)

Safety Profile

MOTS-c has shown excellent tolerability in animal studies across a range of doses. No significant adverse effects have been reported in published research. Given the endogenous nature of the peptide (the body naturally produces it), its safety profile is expected to be favorable, but formal long-term human safety data is not yet available.

MOTS-c in Context: The Mitokine Family

MOTS-c belongs to a broader family of mitochondria-derived peptides that includes humanin and SHLP 1–6 (small humanin-like peptides). Together, these mitokines represent a new paradigm in understanding how mitochondria communicate with the rest of the body to regulate aging, metabolism, and stress responses. Research into all these peptides is accelerating, and MOTS-c is currently the best characterized in terms of metabolic effects.

For more on mitochondrial health and longevity, see our article on mitochondrial health and aging.

Our article on peptide therapy provides broader context on how these compounds are used clinically.

The landmark MOTS-c discovery was published in Cell Metabolism (2015), with follow-up research across Cell, Nature Communications, and Science.